Masitinib for Treatment of Severely Symptomatic Indolent Systemic Mastocytosis: A Randomised, Placebo-Controlled, Phase 3 Study
The Lancet - United Kingdom
doi 10.1016/s0140-6736(16)31403-9
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 1, 2017
Authors
Publisher
Elsevier BV